Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $396000.0.

  • Foghorn Therapeutics' Other Accumulated Expenses rose 8591.55% to $396000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $396000.0, marking a year-over-year increase of 8591.55%. This contributed to the annual value of $1000.0 for FY2024, which is 9722.22% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Other Accumulated Expenses stood at $396000.0 for Q3 2025, which was up 8591.55% from $392000.0 recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Other Accumulated Expenses peaked at $526000.0 during Q1 2025, and registered a low of $1000.0 during Q4 2024.
  • Over the past 5 years, Foghorn Therapeutics' median Other Accumulated Expenses value was $255500.0 (recorded in 2022), while the average stood at $248562.5.
  • Per our database at Business Quant, Foghorn Therapeutics' Other Accumulated Expenses skyrocketed by 20000.0% in 2022 and then tumbled by 9722.22% in 2024.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Other Accumulated Expenses stood at $392000.0 in 2021, then fell by 18.88% to $318000.0 in 2022, then tumbled by 88.68% to $36000.0 in 2023, then plummeted by 97.22% to $1000.0 in 2024, then soared by 39500.0% to $396000.0 in 2025.
  • Its Other Accumulated Expenses was $396000.0 in Q3 2025, compared to $392000.0 in Q2 2025 and $526000.0 in Q1 2025.